2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
25
Neoplasms
12
Giant Cell Tumor of Bone
10
Prostatic Neoplasms
9
Multiple Myeloma
9
Neoplasm Metastasis
8
Osteoporosis
4
Fractures, Bone
4
Carcinoma, Non-Small-Cell Lung
4
Recurrence
3
Kidney Neoplasms
3
Carcinoma, Renal Cell
3
Bone Neoplasms
3
Bone Diseases, Metabolic
3
Bone Diseases
3
Spinal Cord Compression
2
Smoldering Multiple Myeloma
2
Parathyroid Neoplasms
2
Melanoma
2
Lymphoma
2
Lung Neoplasms
2
Giant Cell Tumors
2
Bone Metastases
2
Bone Cysts, Aneurysmal
2
With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer Metastatic
1
Paraproteinemias
1
Interventions
Gemcitabine
685
130-nm albumin-bound paclitaxel
199
Fluorouracil
190
Oxaliplatin
177
Albumin-Bound Paclitaxel
154
Capecitabine
137
Leucovorin
133
Irinotecan
114
Radiotherapy
96
Taxes
85
pembrolizumab
81
Cisplatin
73
Erlotinib Hydrochloride
70
Radiosurgery
69
Nivolumab
56
Drug Therapy
56
Bevacizumab
54
Magnetic Resonance Spectroscopy
51
Cyclophosphamide
50
folfirinox
45
Specimen Handling
43
Docetaxel
42
Cetuximab
40
Biopsy
39
irinotecan sucrosofate
38
S 1 (combination)
36
Pancreaticoduodenectomy
35
Blood Specimen Collection
34
Surgical Procedures, Operative
31
Paclitaxel
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Denosumab
×
Clear all
NCT04907851
2025-03-17
KEYNOTE-E86
Redx Pharma Ltd
Phase 2
Completed
45 enrolled
25 charts